Literature DB >> 25248493

Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells.

Hongcheng Zhu1, Xi Yang, Jia Liu, Lu Zhou, Chi Zhang, Liping Xu, Qin Qin, Liangliang Zhan, Jing Lu, Hongyan Cheng, Xinchen Sun.   

Abstract

Eukaryotic elongation factor 2 (eEF2) is a member of the GTP-binding translation elongation factor family that is essential for protein synthesis. eEF2 kinase (eEF2K) is a structurally and functionally unique protein kinase in the calmodulin-mediated signaling pathway. eEF2K phosphorylates eEF2, thereby inhibiting eEF2 function under stressful conditions. eEF2K regulates numerous processes, such as protein synthesis, cell cycle progression, and induction of autophagy and apoptosis in cancer cells. This review will demonstrate the mechanisms underlying eEF2K activity in cancer cells under different stresses, such as nutrient deprivation, hypoxia, and DNA damage via eEF2 regulation. In vivo, in vitro, and clinical studies indicated that eEF2K may be a novel biomarker and therapeutic target for cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25248493      PMCID: PMC4326389          DOI: 10.1007/s12192-014-0545-0

Source DB:  PubMed          Journal:  Cell Stress Chaperones        ISSN: 1355-8145            Impact factor:   3.667


  28 in total

1.  eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206.

Authors:  Yan Cheng; Xingcong Ren; Yi Zhang; Rajesh Patel; Arati Sharma; Hao Wu; Gavin P Robertson; Li Yan; Eric Rubin; Jin-Ming Yang
Journal:  Cancer Res       Date:  2011-02-09       Impact factor: 12.701

2.  c-Jun-mediated anticancer mechanisms of tylophorine.

Authors:  Cheng-Wei Yang; Yue-Zhi Lee; Hsing-Yu Hsu; Chia-Mao Wu; Hwan-You Chang; Yu-Sheng Chao; Shiow-Ju Lee
Journal:  Carcinogenesis       Date:  2013-02-05       Impact factor: 4.944

Review 3.  The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine.

Authors:  Lisa M Monteggia; Erinn Gideons; Ege T Kavalali
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

4.  The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.

Authors:  Gabriel Leprivier; Marc Remke; Barak Rotblat; Adrian Dubuc; Abigail-Rachele F Mateo; Marcel Kool; Sameer Agnihotri; Amal El-Naggar; Bin Yu; Syam Prakash Somasekharan; Brandon Faubert; Gaëlle Bridon; Cristina E Tognon; Joan Mathers; Ryan Thomas; Amy Li; Adi Barokas; Brian Kwok; Mary Bowden; Stephanie Smith; Xiaochong Wu; Andrey Korshunov; Thomas Hielscher; Paul A Northcott; Jason D Galpin; Christopher A Ahern; Ye Wang; Martin G McCabe; V Peter Collins; Russell G Jones; Michael Pollak; Olivier Delattre; Martin E Gleave; Eric Jan; Stefan M Pfister; Christopher G Proud; W Brent Derry; Michael D Taylor; Poul H Sorensen
Journal:  Cell       Date:  2013-05-23       Impact factor: 41.582

Review 5.  The role of protein synthesis in cell cycling and cancer.

Authors:  Shai White-Gilbertson; David T Kurtz; Christina Voelkel-Johnson
Journal:  Mol Oncol       Date:  2009-06-11       Impact factor: 6.603

6.  Phosphorylation of eukaryotic elongation factor 2 (eEF2) by cyclin A-cyclin-dependent kinase 2 regulates its inhibition by eEF2 kinase.

Authors:  Asli A Hizli; Yong Chi; Jherek Swanger; John H Carter; Yi Liao; Markus Welcker; Alexey G Ryazanov; Bruce E Clurman
Journal:  Mol Cell Biol       Date:  2012-11-26       Impact factor: 4.272

Review 7.  Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles.

Authors:  Justin W Kenney; Claire E Moore; Xuemin Wang; Christopher G Proud
Journal:  Adv Biol Regul       Date:  2014-04-30

8.  Comparative proteomic analysis implicates eEF2 as a novel target of PI3Kγ in the MDA-MB-231 metastatic breast cancer cell line.

Authors:  Meizhi Niu; Manuela Klingler-Hoffmann; Julie A Brazzatti; Briony Forbes; Chareeporn Akekawatchai; Peter Hoffmann; Shaun R McColl
Journal:  Proteome Sci       Date:  2013-01-15       Impact factor: 2.480

9.  Hypoxia integration in the serological proteome analysis unmasks tumor antigens and fosters the identification of anti-phospho-eEF2 antibodies as potential cancer biomarkers.

Authors:  Marie Grandjean; Alexandra Sermeus; Samuel Branders; Florence Defresne; Marc Dieu; Pierre Dupont; Martine Raes; Mark De Ridder; Olivier Feron
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

10.  Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.

Authors:  Ibrahim Tekedereli; S Neslihan Alpay; Clint D J Tavares; Zehra E Cobanoglu; Tamer S Kaoud; Ibrahim Sahin; Anil K Sood; Gabriel Lopez-Berestein; Kevin N Dalby; Bulent Ozpolat
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

View more
  10 in total

1.  MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma.

Authors:  Qianqian Shi; Xianlin Xu; Qing Liu; Fengbao Luo; Jian Shi; Xiaozhou He
Journal:  Oncol Lett       Date:  2015-12-31       Impact factor: 2.967

2.  FOXM1 plays a role in autophagy by transcriptionally regulating Beclin-1 and LC3 genes in human triple-negative breast cancer cells.

Authors:  Zuhal Hamurcu; Nesrin Delibaşı; Ufuk Nalbantoglu; Elif Funda Sener; Nursultan Nurdinov; Bayram Tascı; Serpil Taheri; Yusuf Özkul; Hamiyet Donmez-Altuntas; Halit Canatan; Bulent Ozpolat
Journal:  J Mol Med (Berl)       Date:  2019-02-07       Impact factor: 4.599

3.  Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation.

Authors:  Qinghua Fu; Xiaomei Liu; Yan Li; Peng Wang; Tian Wu; Haihan Xiao; Yameng Zhao; Qichao Liao; Ziyi Song
Journal:  Molecules       Date:  2022-07-30       Impact factor: 4.927

4.  Coordination of changes in expression and phosphorylation of eukaryotic elongation factor 2 (eEF2) and eEF2 kinase in hypertrophied cardiomyocytes.

Authors:  Satoshi Kameshima; Muneyoshi Okada; Shiro Ikeda; Yuki Watanabe; Hideyuki Yamawaki
Journal:  Biochem Biophys Rep       Date:  2016-06-28

5.  MicroRNA-143-5p targeting eEF2 gene mediates intervertebral disc degeneration through the AMPK signaling pathway.

Authors:  Qi Yang; Xiao-Peng Guo; Yan-Li Cheng; Yang Wang
Journal:  Arthritis Res Ther       Date:  2019-04-15       Impact factor: 5.156

Review 6.  mRNA-to-protein translation in hypoxia.

Authors:  Nancy T Chee; Ines Lohse; Shaun P Brothers
Journal:  Mol Cancer       Date:  2019-03-30       Impact factor: 27.401

7.  SIRT1 Protects the Heart from ER Stress-Induced Injury by Promoting eEF2K/eEF2-Dependent Autophagy.

Authors:  Julie Pires Da Silva; Kevin Monceaux; Arnaud Guilbert; Mélanie Gressette; Jérôme Piquereau; Marta Novotova; Renée Ventura-Clapier; Anne Garnier; Christophe Lemaire
Journal:  Cells       Date:  2020-02-12       Impact factor: 6.600

8.  Targeting Protein Translation in Melanoma by Inhibiting EEF-2 Kinase Regulates Cholesterol Metabolism though SREBP2 to Inhibit Tumour Development.

Authors:  Saketh S Dinavahi; Yu-Chi Chen; Raghavendra Gowda; Pavan Kumar Dhanyamraju; Kishore Punnath; Dhimant Desai; Arthur Berg; Scot R Kimball; Shantu Amin; Jin-Ming Yang; Gavin P Robertson
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

9.  Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway.

Authors:  Bingbing Dai; Jithesh J Augustine; Ya'an Kang; David Roife; Xinqun Li; Jenying Deng; Lin Tan; Leona A Rusling; John N Weinstein; Philip L Lorenzi; Michael P Kim; Jason B Fleming
Journal:  Cell Death Dis       Date:  2021-07-10       Impact factor: 8.469

10.  Identification of HSPA8 as a candidate biomarker for endometrial carcinoma by using iTRAQ-based proteomic analysis.

Authors:  Nianchun Shan; Wei Zhou; Shufen Zhang; Yu Zhang
Journal:  Onco Targets Ther       Date:  2016-04-13       Impact factor: 4.147

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.